Returning from the afterlife?Sotorasib treatment for advanced KRAS mutant lung cancer:A case report  

作　　者：Ming-Xing Wang Pei Zhu Yue Shi Qing-Ming Sun Wan-Hui Dong 

机构地区：[1]Department of Medical Oncology,Lu’an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine,Lu’an 237000,Anhui Province,China [2]Department of Medical Oncology,Lu’an Hospital of Traditional Chinese Medicine,Lu’an 237000,Anhui Province,China

出　　处：《World Journal of Clinical Cases》2024年第25期5805-5813,共9页世界临床病例杂志

摘　　要：BACKGROUND Lung cancer is increasing in incidence worldwide,and targeted therapies are developing at a rapid pace.Furthermore,the KRAS specific gene is strongly associated with non-small cell lung cancer(NSCLC).Adult patients with locally advanced or metastatic NSCLC who have tested positive for the KRAS G12C mutation and have progressed after at least one systemic treatment are treated with sotorasib.CASE SUMMARY In this study,we report on an advanced NSCLC with a KRAS G12C mutation.The histological diagnosis indicates stage IVB left lung adenocarcinoma with pelvic and bone metastases,identified as cT4N2bM1c.Using circulating tumor DNA analysis,it was possible to determine the mutation abundance of the KRAS gene exon 2,c.34G>Tp.G12C,which was 32.3%.The patient was advised to take sotorasib as part of their treatment.The imaging data were compared before and after treatment.Furthermore,clinical reassessments and regular serial blood testing were conducted.We found that the patient’s clinical symptoms significantly improved after receiving sotorasib medication,and there were no notable side effects,such as liver toxicity,during the treatment.CONCLUSION Sotorasib has shown promising clinical efficacy in patients with the KRAS G12c mutation and has no apparent toxic side effects.

关 键 词：Non-small cell lung cancer Sotorasib KRAS G12C Targeted therapy Advanced carcinoma Case report 

分 类 号：R734.2[医药卫生—肿瘤]